Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLAFEM 1/35 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
400 mg orally once daily with food.
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol: CYP3A4, sulfation, glucuronidation. Norethindrone: CYP3A4, reduction, conjugation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Norethindrone is 80-85% bound to SHBG and albumin; ethinyl estradiol is 95-98% bound to albumin.
98% bound to albumin
Norethindrone Vd is 1.2-2.4 L/kg; ethinyl estradiol Vd is 2.5-4.5 L/kg.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral bioavailability: norethindrone 50-60%; ethinyl estradiol 40-50% due to first-pass metabolism.
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment studied.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use in postmenarchal minors before menarche. For adolescents, same adult dosing (one tablet daily) after menarche. Safety and efficacy established in postmenarchal females.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women. Avoid use in women over 50 years due to increased risk of thrombosis and no benefit for contraception. If used, no specific dose adjustment, but consider non-hormonal alternatives.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events from COC use. Risk increases with age and heavy smoking (>=15 cigarettes/day). Women over 35 who smoke should not use COCs.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Thrombotic disorders (DVT, PE, MI, stroke),Hepatic neoplasia (benign and malignant),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Hereditary angioedema exacerbation,Chloasma,Ocular lesions (retinal thrombosis, optic neuritis),Depression,Menstrual irregularities/breakthrough bleeding
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders,History of DVT/PE,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy/COC-related jaundice,Benign/malignant hepatic adenoma,Pregnancy,Hypersensitivity to any component,Age >35 and smoking >=15 cigarettes/day
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No significant food interactions. However, grapefruit juice may increase ethinyl estradiol levels via CYP3A4 inhibition, though clinical significance is uncertain. Avoid excessive alcohol intake as it may impair liver function and reduce contraceptive efficacy. Maintain a balanced diet, as folate supplementation may be beneficial due to potential folate depletion with oral contraceptives.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction defects. Second and third trimesters: Associated with fetal genital abnormalities (masculinization of female fetuses) and potential for other congenital anomalies. Postnatal: Possible long-term neurodevelopmental effects.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Compatible with breastfeeding. Norethindrone and ethinyl estradiol are excreted in breast milk in small amounts. M/P ratio: Norethindrone ~0.5-0.7; ethinyl estradiol ~0.1-0.3. No adverse effects reported in infants at recommended doses. May reduce milk volume and protein content; use lowest effective dose.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Not applicable; drug is contraindicated during pregnancy. No dose adjustments are recommended because use is contraindicated. If inadvertent exposure occurs, discontinue immediately.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
CYCLAFEM 1/35 is a monophasic oral contraceptive containing norethindrone (1 mg) and ethinyl estradiol (35 mcg). For missed pills: if one pill is missed, take it as soon as remembered, even if it means taking two pills in one day. If two pills are missed in Week 1 or 2, take two pills on the day remembered and two the next day, then resume regular schedule; use backup contraception for 7 days. If two pills are missed in Week 3 or three or more pills are missed at any time, discard the rest of the pack and start a new pack that day; use backup contraception for 7 days. Monitor for breakthrough bleeding, which is common in the first few cycles. Avoid use in women with uncontrolled hypertension, migraine with aura, or history of thromboembolism.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one tablet daily at the same time each day; do not skip doses.,If you miss a pill, refer to the missed pill instructions in the package insert or consult your healthcare provider.,Use additional non-hormonal contraception (e.g., condoms) for 7 days after missing pills as directed.,Report any signs of thromboembolism (leg pain, chest pain, shortness of breath) or stroke (sudden severe headache, visual changes, speech difficulty) immediately.,Smoking increases the risk of serious cardiovascular side effects; avoid smoking while taking this medication.,This medication does not protect against HIV or other sexually transmitted infections.,Expect spotting or light bleeding between periods, especially in the first few months.,If you have vomiting or diarrhea, use backup contraception and consult your healthcare provider.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLAFEM 1/35 vs ADQUEY, answered by our medical review team.
CYCLAFEM 1/35 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLAFEM 1/35 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLAFEM 1/35 is: One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLAFEM 1/35 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLAFEM 1/35 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: Increased risk of neural tube defects, cardiovascular anomalies, and limb reduction d. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.